Phaxiam: little reaction to strategic point

(CercleFinance.com) - Last night, Phaxiam gave an update on the deployment of its strategy in phages, natural bacteria-killing viruses, an announcement that didn't create much of a stir in its share price.


In a press release, the biopharmaceutical company explains that it intends to focus its approach on two complementary development axes, namely individualized GMP phage-based therapies (IPT) and phage drugs (PTMP).

However, the company specifies that it intends to give priority to its IPT activities, with the aim of generating revenues as early as 2026 and achieving sales of around 20 million euros by 2027.

In this respect, Phaxiam states that it has joined forces with another European player in the sector, Technophage, with the aim of expanding its portfolio to 25 GMP phages by the end of 2025, and accelerating the deployment of individualized treatments.

With regard to phage-drugs (PTMPs), the company says it intends to pursue the development of its model through clinical trials and new compassionate access authorizations (CAAs).

With cash and cash equivalents reaching 3.6 million euros at December 31, 2024, Phaxiam says it is seeking financing that would enable it to extend its financial horizon beyond March 2025.

At the same time, Phaxiam is continuing to prepare the Gloria Phase II study, the world's first phagotherapy trial in osteoarticular infections on prostheses.

On the Paris Bourse, the share price was trading without much direction (+0.8%) late Friday morning in the wake of these announcements. The stock is down nearly 48% year-on-year.

Copyright (c) 2025 CercleFinance.com. All rights reserved.